Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan
International Journal of Gynecology & Obstetrics · 2025
DOI: 10.1002/ijgo.16125 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2025. Verfasst von Naohiro Takamoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Early Detection of Cancer, Papillomavirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
In Japan, the current coverage rate of human papillomavirus (HPV) vaccination is only 30%, and the rate of biennial cervical screening is 40%. The Japanese Government has attempted to increase the coverage of HPV vaccination and cervical screening. We analyzed the cost‐effectiveness of the 9‐valent HPV vaccine and cervical screening in Japan.
Methods
A yearly cycle Markov model with 15 health states was created to evaluate the cost‐effectiveness of the 9‐valent HPV vaccination and cervical screening in women aged 12–75 years. We considered four scenarios: 30% coverage of vaccination with 40% coverage of biennial screening (Scenario 1 representing the current Japanese situation), 70% (the highest proportion in 2013 in Japan) and 90% coverage of vaccination with 40% coverage of biennial screening (Scenarios 2 and 3, respectively), and 90% coverage of vaccination with 70% coverage of biennial screening (Scenarios 4). The incremental cost‐effectiveness ratio (ICER) was calculated as costs per quality‐adjusted life year (QALY) based on the perspective of the healthcare payer and compared with the benchmark for willingness to pay in Japan (41 700 USD per QALY). The cumulative morbidity and mortality in each scenario were analyzed using the Markov model.
Results
Compared with Scenario 1, the ICERs of Scenarios 2, 3, and 4 were 5382, 5321, and 8524 USD/QALY, respectively, which were lower than the benchmark for willingness to pay. As the coverage of HPV vaccination and cervical screening increased, the cumulative morbidity and mortality decreased.
Conclusion
Increasing the coverage of the 9‐valent HPV vaccination and cervical screening is cost‐effective in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
ORCID-Profile: Naohiro Takamoto
Zitieren
APA
Takamoto, N., Aso, S., Ishida, R., Konishi, T., Fushimi, K., & Yasunaga, H. (2025). Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.16125
Vancouver
Takamoto N, Aso S, Ishida R, Konishi T, Fushimi K, Yasunaga H. Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan. International Journal of Gynecology & Obstetrics. 2025. doi:10.1002/ijgo.16125
BibTeX
@article{Takamoto2025,
author = {Takamoto, Naohiro and Aso, Shotaro and Ishida, Risa and Konishi, Takaaki and Fushimi, Kiyohide and Yasunaga, Hideo},
title = {Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan},
journal = {International Journal of Gynecology & Obstetrics},
year = {2025},
doi = {10.1002/ijgo.16125}
}
EUVIMED